NITROFURANTOIN MONO MAC 100MG CAPS 101 FULL
Patients should be instructed to complete the full course of therapy however, they should be advised to contact their physician if any unusual symptoms occur during therapy. Patients should be advised to take nitrofurantoin macrocrystals capsules with food to further enhance tolerance and improve drug absorption. difficile, and surgical evaluation should be instituted as clinically indicated. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. CDAD must be considered in all patients who present with diarrhea following antibiotic use. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. difficile produces toxins A and B which contribute to the development of CDAD. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. In considering the use of nitrofurantoin macrocrystals capsules, lower eradication rates should be balanced against the increased potential for systemic toxicity and for the development of antimicrobial resistance when agents with broader tissue distribution are utilized.Ĭlostridium difficile -associated diarrhea:Ĭlostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including nitrofurantoin, and may range in severity from mild diarrhea to fatal colitis. If persistence or reappearance of bacteriuria occurs after treatment with nitrofurantoin macrocrystals capsules, other therapeutic agents with broader tissue distribution should be selected. Urine specimens for culture and susceptibility testing should be obtained before and after completion of therapy. Consequently, many patients who are treated with nitrofurantoin macrocrystals capsules are predisposed to persistence or reappearance of bacteriuria. Nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for urinary tract infections. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. To reduce the development of drug-resistant bacteria and maintain the effectiveness of nitrofurantoin macrocrystals capsules and other antibacterial drugs, nitrofurantoin macrocrystals capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. Nitrofurantoin macrocrystals capsules is specifically indicated for the treatment of urinary tract infections when due to susceptible strains of Escherichia coli, enterococci, Staphylococcus aureus, and certain susceptible strains of Klebsiella and Enterobacter species.
0 kommentar(er)
